AI Article Synopsis
- Intrahepatic sarcomatoid cholangiocarcinoma (s-CCC) is a rare liver cancer, accounting for less than 1% of hepatobiliary malignancies, and its symptoms mainly include abdominal pain and fever.
- A case study of a 32-year-old male with a history of chronic hepatitis B revealed a liver mass diagnosed as s-CCC after surgical removal and pathological testing, which showed specific markers like vimentin and cytokeratin.
- Post-surgery, the patient received a combination of albumin-paclitaxel and gemcitabine treatments, and after six months of follow-up, there was no evidence of cancer recurrence.
Article Abstract
As a rare disease, intrahepatic sarcomatoid cholangiocarcinoma (s-CCC) represents less than 1% of malignancies of the hepatobiliary system and its main clinical symptoms include abdominal pain and fever. Results of pathological examinations, despite being the "gold standard", can easily be confused with hepatocellular carcinoma (HCC). This report is about a 32-year-old male patient who was hospitalized due to occupancy of segment V of the liver for three days and had a history of chronic hepatitis B (CHB) over a 20-year span. Magnetic resonance imaging (MRI) showed a 43 mm × 52 mm-sized liver mass in the V segment, with patchy peripheral enhancement during the arterial phase and rapid wash-out during the portal and late phases. A laparoscopic hepatectomy of segment V, along with cholecystectomy, was performed. Histopathological and immunohistochemical examinations indicated a malignant neoplasm that was positive for vimentin and cytokeratin, with these features providing a positive diagnosis for intrahepatic sarcomatoid cholangiocarcinoma. After surgery, an adjuvant therapy of albumin-paclitaxel combined with gemcitabine regimen was given. No recurrence was found six months after the surgery, with follow-up still ongoing. This report aims to improve the awareness, diagnosis, and treatment of s-CCC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476318 | PMC |
| http://dx.doi.org/10.3389/fsurg.2022.963952 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hepatic adenosquamous carcinoma with sarcomatous transformation: a case report and review of the literature.
Med Mol Morphol
October 2024
Department of Human Pathology, Kanazawa University Graduate School of Medical Sciences, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8640, Japan.
Article Synopsis
- Adenosquamous carcinoma (ASC) with a sarcomatous element is a rare form of intrahepatic cholangiocarcinoma (iCCA), and this case focuses on a unique occurrence involving rhabdoid transformation.
- A 72-year-old male presented with a large neoplastic lesion in the right hepatic duct, and subsequent surgery revealed a tumor composed of both ASC and a sarcomatoid carcinoma component with distinct immunohistochemical profiles.
- Unfortunately, the patient experienced liver failure and passed away three months post-surgery, highlighting the aggressive nature of this uncommon cancer variant and emphasizing the need for improved diagnostic and treatment strategies.
Pathologic features and clinical treatment of sarcomatoid intrahepatic cholangiocarcinoma.
Intractable Rare Dis Res
November 2023
Department of Pathology, Minhang Hospital, Fudan University, Shanghai, China.
The current study examined sarcomatoid intrahepatic cholangiocarcinoma (S-iCCA). S-iCCA was a more aggressive subtype of intrahepatic cholangiocarcinoma (iCCA). Early detection and complete resection of tumors are very important.
View Article and Find Full Text PDFDynamic contrast-enhanced CT and clinical features of sarcomatoid hepatocellular carcinoma.
Abdom Radiol (NY)
October 2023
Department of Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, No.250, Changgang East Road, Haizhu District, Guangzhou, 510399, Guangdong, China.
Purpose: To investigate the dynamic contrast-enhanced computed tomography (CECT) features and clinical characteristics of sarcomatoid hepatocellular carcinoma (S-HCC).
Methods: We retrospectively reviewed the CECT data and clinical findings of 13 patients (11 male and 2 female, with an average age of 58.6 ± 11.
Sarcomatoid Intrahepatic Cholangiocarcinoma: A Rare and Aggressive Primary Liver Cancer.
Cureus
May 2023
Department of Internal Medicine, Ascension Saint Joseph Hospital, Chicago, USA.
Sarcomatoid intrahepatic cholangiocarcinoma (S-iCCA) is a rare variant of primary liver cancer with a poor prognosis due to local aggressive expansion and frequent metastases. The pathogenesis remains unclear, but theories suggest epithelial-mesenchymal transition, biphasic differentiation of pluripotent stem cells, or sarcomatoid re-differentiation of immature multipotent carcinoma cells. Chronic hepatitis B and C, cirrhosis, and age above 40 are plausible contributors.
View Article and Find Full Text PDFImmune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice.
Lancet Gastroenterol Hepatol
August 2023
Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
Article Synopsis
- Systemic therapy for advanced hepatocellular carcinoma has rapidly evolved over the last 5 years, shifting from tyrosine kinase inhibitors to immune checkpoint inhibitors (ICIs) as the main treatment option.
- The article addresses significant knowledge gaps regarding the effectiveness of ICI therapies in patients with Child-Pugh class B liver disease and in those with rare liver cancer subtypes.
- Additionally, it reviews the concept of ICI rechallenge in previously treated patients and explores unusual disease progression patterns linked to immunotherapy, such as hyperprogressive disease and pseudoprogression.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!